Genome Atlas Research Network, presents a comprehensive genomic analysis of human oesophageal squamous-cell carcinomas (ESCCs) and oesophageal adenocarcinomas (EACs) 1 . These are the two major subtypes of oesophageal cancer recognized according to microanatomical categorization, and together they cause more than 400,000 deaths worldwide each year 2 . The study reveals previously unknown genomic aberrations -a discovery that may lead to more-rational clinical trials for oesophageal cancer treatments. Furthermore, it provides evidence that oesophageal and gastric cancers should be stratified by molecular features, rather than by anatomical site.
The Cancer Genome Atlas Research Network (https://cancergenome.nih.gov) produces open-access genomic data about human cancers. Together with other similar projects, it has revealed the genomic landscape of many types of human cancer across nearly all organ sites, confirming some previously understood similarities and differences between cancers and uncovering unexpected molecular profiles that might lead to new avenues for cancer prevention and treatment 3 .
In the current study, the consortium first demonstrated that ESCCs and EACs have distinct molecular profiles through superhydrophobic surfaces would quickly degrade.
In the authors' experiment, preheated water was contained in the gap between two concentric cylinders and driven by rotation of the inner cylinder (Fig. 1) . The superhydrophobic surface of the inner cylinder was heated to 160 °C and a stable vapour layer formed, reducing drag by up to 90% compared with that on an ordinary surface. Saranadhi et al. calculated that the amount of slip at the heated surface was approximately 100 times larger than the maximum slip obtained using standard superhydrophobic surfaces. They attributed this result to the unusually large thickness of the vapour layer (about 50 micrometres) and the fact that the layer fully encloses the surface -including its microstructure, which in unheated superhydrophobic surfaces would be partially exposed to the surrounding liquid.
Materials that can sustain large slip amplitudes in macroscopic flows have long been sought. At present, these materials work only under special conditions (in this case, high temperature) and are unlikely to find widespread application. Additionally, replenishing the vapour film currently consumes more energy than is saved by the reduction in drag. Nevertheless, the emergence of materials that, in principle, can provide partial slip at solid-fluid interfaces is a big step forward and will spur further research.
The authors' results might also be relevant to research on turbulence. In wall-bounded flows (such as pipes), turbulence is essentially sustained by the friction between the fluid and the wall. Introducing partial slip and observing how turbulence adapts to these new conditions could provide fundamental insights into the turbulence-sustaining mechanism.
The quest for materials that promote lowfriction fluid transport bears some resemblance to the search for room-temperature superconductors 4 (materials with zero electrical resistance). Whereas present-day superconductors 5 work only at temperatures below 0 °C, for their classical-physics counterpartfluid-drag reduction -the largest sustained slip obtained by the authors occurs at temperatures above room temperature. If either effect can hit the room-temperature target, it is likely to have a major impact on global energy consumption. ■ 
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Spot the difference
A molecular analysis of human oesophageal cancers reveals abnormalities that might be targetable by existing drugs, and indicates that the current stratification of these tumours into subtypes is incomplete. See Article p.169 1 carry out an experiment that uses water contained between two concentric cylinders. The inner cylinder rotates with respect to the outer cylinder, driving water flow through the system. The velocity of the water flow is illustrated here by a fluid-velocity profile, in which the length of each arrow is proportional to the velocity at that point (in the reference frame of the inner cylinder). The surface of the inner cylinder is superhydrophobicit is irregular and rough, which causes air to be trapped in the recesses. By continuously heating the inner cylinder, the authors observe the appearance of a vapour film that coats the superhydrophobic surface. This film reduces frictional drag at the interface between the inner cylinder and the water, and is maintained even when the system is subjected to large shear stresses and turbulent flow conditions. (Adapted from ref. 1.) DNA sequencing, analyses of gene and protein expression and analyses of methylation of DNA (which can lead to alterations in gene expression). The authors outline several biological pathways that are genetically altered in ESCC, EAC or both, and which confirm the need for different therapeutic strategies in these two diseases.
Analysis of genetic copynumber alterations (in which large portions of a chromosome are deleted or replicated, altering gene-expression levels) revealed amplification of several different genes in ESCC and EAC. For instance, amplification of the genes ERBB2 and VEGFA was found in samples from EAC but not ESCC. An inhibitor of ERBB2 called trastuzumab has been approved for use by the US Food and Drug Administration, and an inhibitor of the VEGF signalling pathway called ramucirumab is frequently used in a subset of EACs -these therapies can now be quickly deployed in patients who harbour these genetic mutations. By contrast, mutations that lead to dysregulation of the cell cycle occurred in both ESCC and EAC. As the authors suggest, available inhibitors of cell-cycle proteins such as the drug palbociclib might effectively combat both diseases.
The division of ESCCs and EACs into further subgroups could lead to more-effective, precision treatments. The consortium identified subgroups within ESCC that were characterized by specific genetic alterations. The first subgroup was characterized mainly by mutations that activated the NRF2 signalling pathway, including activating mutations in the NFE2L2 gene, which is associated with resistance to chemoradiotherapy and poor patient outcome 4 . NFE2L2 encodes a transcription factor, whose activity is inhibited by the protein KEAP1 -this pathway could therefore potentially be targeted for treatment if drugs could be developed to inhibit mutant, activated NRF2. Intriguingly, molecular features of this ESCC class bear a striking resemblance to classical subtypes of lung and head and neck cancers (Fig. 1) , suggesting that these diseases may respond similarly to targeted therapies.
The second ESCC subgroup is characterized in part by a decrease in DNA methylation compared with the other subgroups and by overexpression of the gene BST2, which encodes a protein that modulates immune activity and that is associated with poor prognosis in ESCC (ref. 5). Here, too, there is therapeutic potential, because an anti-BST2 antibody has shown antitumour activity in other cancers [6] [7] [8] . The third subtype is characterized by mutation in the gene SMARCA4 and activation of the PI3K signalling pathway. PI3K inhibitors that are currently in clinical trials may therefore be effective in this subgroup.
There has been some debate about how to classify EACs that arise near to or at the entrance to the stomach, because it can be unclear on which side of the gastroesophageal junction the tumour originated. So the authors next sought to compare molecular features of EAC with those of gastric cancers. The findings indicate a striking similarity between EAC and one subtype of gastric cancer, denoted as having chromosomal instability (CIN). Recurrent gene amplifications are shared between EAC and gastric CIN tumours, but not between EAC and ESCC. Although there are subtle differences in the frequencies at which some genetic alterations arise, the authors' evidence indicates that EAC and gastric CIN are the same disease at the molecular level (Fig. 1) .
This study is an excellent example of the potential for molecular technologies and bioinformatic approaches to contribute to our understanding of human disease. Conventionally, cancers are treated according to where they arise in the body and their appearance under a microscope. We now understand that cancers that develop in the same location can vary greatly at the molecular level. Treatment decisions made without this new wealth of genomic data can lead to patients receiving a drug that is unlikely to be beneficial, or not receiving one predicted to be effective. Many cancers continue to be treated on the basis of organ site alone, but clinicians are beginning to embrace molecular-classification systems -a trend that is likely to accelerate as similar studies are conducted across cancer types.
Clinical trials mainly enrol patients who have cancers at the same organ site. But the current study demonstrates that EAC and ESCC should be separated in the clinical setting so that each can be targeted according to its specific genomic features. In addition, basket clinical trials (in which multiple organ sites are combined on the basis of common molecular features) can now pool ESCC with head and neck cancer, and EAC with gastric CIN cancer, to maximize the benefit to patients and accelerate the approval of effective therapies for each disease. Large-scale genomic studies such as this one may thereby hold the key that unlocks the promise of precision medicine. 
CORRECTION
The News & Views article 'Cancer genomics: spot the difference' by Noah D. Peyser and Jennifer R. Grandis (Nature 541, 162-163; 2017) incorrectly stated that drugs that inhibit the activity of the protein KEAP1, which itself inhibits the transcription factor NRF2, could be used to combat activating mutations in the gene that encodes NRF2. Instead, it should have stated that this pathway could potentially be targeted for therapeutic use in certain oesophageal cancers if drugs are developed to inhibit mutant, activated NRF2.
